

FIG. 1





FIG. 2A





FIG. 3A





FIG. 3B



A – Anti-BCMA CAR T cells alone
B – 1 nM Compound A
C – 10 nM Compound A
D – 0.1 nM Compound B
E – 1 nM Compound B





FIG. 4B



A – Anti-BCMA CAR T cells alone
B – 1 nM Compound A
C – 10 nM Compound A
D – 0.1 nM Compound B
E – 1 nM Compound B





FIG. 5B

Mean (SD) cytokine measurement at days 5 and 9 after 24 hours of reset



BLI
Mean/Group

FIG. 6A





FIG. 6B

Survival



Iberdomide Sensitive
OPM2 Model

FIG. 6C




FIG. 7A

BLI
Mean/Group




FIG. 7B

Survival




FIG. 7C

DF-15(R) Disseminated MM Xenograft Model (Iberdomide-resistant)




FIG. 8




FIG. 9A




FIG. 9B




FIG. 9C




FIG. 9D




FIG. 10A




FIG. 10B







FIG. 11A




FIG. 11B




FIG. 11C




FIG. 11D

